Liver cancers armed with many strategies for evading immune response

(Medical Xpress)—Researchers at Roswell Park Cancer Institute (RPCI) have published findings that help explain how a common and particularly resilient form of liver cancer evades the body's natural antitumor responses. The study, published April 15 in the journal Cancer Research, a publication of the American Association for Cancer Research (AACR), is the first to examine the combined effect of immunosuppression on immune function in advanced hepatocellular carcinoma (HCC), the fifth-most-common cancer in the world and the third-leading cause of cancer-related mortality globally.

In a study involving 23 patients with , Yasmin Thanavala, PhD, a Professor of Oncology in the Department of Immunology, and colleagues measured multiple parameters of simultaneously, revealing a previously undescribed picture of extreme immune dysfunction in patients with advanced HCC.

Therapeutic options for patients with inoperable HCC tumors are limited, the authors note. "Unfortunately, most patients with HCC are first diagnosed with the disease at an advanced stage or present with poor ," they write, "thereby preventing the use of potentially curative therapies." They concluded that the findings warrant further study in the clinical setting.

"We found that HCC patients accumulate an unusually high number and variety of immunosuppressive cells, which allows them to impede immunotherapies and facilitate ," says Dr. Thanavala, the study's senior author. "What we learned from this detailed analysis is that immunotherapies that have been shown to deplete these particular are likely to be effective in restoring immune function for HCC patients—especially when combined with approaches that bolster the cancer-fighting T cells."

Co-authors are Suresh Kalathil, PhD, and Amit Lugade, PhD, from the Department of Immunology; Austin Miller, PhD, Assistant Professor of Oncology in the Department of Biostatistics & Bioinformatics; and Renuka Iyer, MD, Associate Professor of Oncology and Co-Director of the Liver and Pancreas Tumor Program.

This work was supported in part by the National Cancer Institute's Cancer Center Support Grant to RPCI (P30CA016056) and by funding from the American Cancer Society.

The paper, "Higher frequencies of GARP+ CTLA-4+ Foxp3+ T regulatory cells and myeloid-derived suppressor cells in patients are associated with impaired T cell functionality," is available online at http://goo.gl/wwzdI

add to favorites email to friend print save as pdf

Related Stories

Personalized treatment may help some liver cancer patients

Oct 22, 2010

A more personalized treatment for people with a type of metastatic liver cancer --hepatocellular carcinoma -- may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers. Hepatocellular ...

Recommended for you

The fine line between breast cancer and normal tissues

5 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

6 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

9 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

10 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments